IMV Inc. completes public offering of units for proceeds of approximately US$25M

On July 20, 2021, IMV Inc. closed an underwritten public offering of 14,285,714 units, for total gross proceeds of US$25 million. IMV intends to use the net proceeds of the offering to further several of its clinical developments and for general corporate purposes.

IMV is a biopharmaceutical company based in Dartmouth, Nova Scotia. It is focused on creating more effective immunotherapies for cancer and other diseases.

McCarthy Tétrault advised IMV with a team led by Philippe Leclerc that included Myreille Gilbert and Mireille Trottier (Securities), and Marie-Soleil Landry and Geneviève Favreau (Tax).